PetVivo Holdings, Inc. Eliminates Chief Operating Officer Position in Cost-Cutting Move

PetVivo Holdings, Inc. (NASDAQ: PETVW) recently announced the elimination of the Chief Operating Officer (COO) position, effective immediately, as part of the company’s cost-cutting initiatives. This decision, made on January 31, 2025, was in accordance with the directive of the Board of Directors.

As a result of this move, the employment of Randall A. Meyer, who has been serving as the COO since approximately November 10, 2021, was terminated. The duties and responsibilities previously held by the COO will now be distributed among several key individuals within the organization. Josh Wilhelm, the Vice President of Operations and Research and Development, Zach Swanson, the Director of Manufacturing and Lab Operations, Dave Heller, the Quality Systems Manager, and Jeremy Kaplan, the Director of Research and Development, will collectively take on the tasks previously handled by the COO.

In expressing gratitude for Mr. Meyer’s service and contributions to the company, PetVivo Holdings, Inc. extended best wishes to him in his future endeavors.

PetVivo Holdings, Inc. is listed on the OTCQB under the trading symbols PETV for Common Stock and PETVW for Warrants. The company is currently classified as an emerging growth company as defined by Rule 405 of the Securities Act of 1933.

For more information, interested parties can refer to the official Form 8-K filed by PetVivo Holdings, Inc. with the Securities and Exchange Commission on January 31, 2025.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those contemplated by these statements due to various factors. The company disclaims any obligation to update these forward-looking statements.

-END-

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read PetVivo’s 8K filing here.

About PetVivo

PetVivo Holdings, Inc, a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses.